21st Century Cures Act

Recorded December 21, 2016 | On-Demand Webinar

The 21^st Century Cures Act—signed into law by the President on Tuesday, December 13, is sweeping bipartisan legislation intended to advance the research and development of new therapies and diagnostics and that makes substantial federal investments in a wide range of health care priorities. The Act’s changes to the Federal Food, Drug, and Cosmetic Act are significant, clarifying and creating new FDA authorities over drugs, including regenerative advanced therapies; medical devices, including certain health software; and combination products; as well as FDA’s administrative authorities. Join FDLI for an overview of the FDA-related sections of this new law while hearing directly from those intimately involved in the legislation.

Eva Temkin, Counselor, Office of the Chief Counsel, FDA
Wade Ackerman, Partner, Covington & Burling LLP
Marcy Busch, Counselor, Office of Chief Counsel, FDA
Moderated by Carla Cartwright, Director, Global Regulatory Policy & Intelligence, Janssen Pharmaceuticals Inc.

Get Access

$99

+$100 for non-members

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

Virtual Learning FAQ

When will I receive my session?

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

Is my computer/mobile device compatible?

On-demand content can be played back on most devices.

If you have concerns, please click the Test Your System link to determine your device's compatibility, as well as system requirements.

Is CLE credit available?

CLE credit is not currently available for pre-recorded sessions.

Related Content

FDA’s Legal Authority Over Laboratory Developed Tests

Compounding Drug Products Due to Supply Chain Access in Light of COVID-19

FDA’s Compounding Memorandum of Understanding with States: Questions, Concerns, and What’s Next

Continued Reliance on Foreign Drug Manufacturing and the Drug Supply Chain: Manageable Risk or Public Health Concern?

State of FDA Medical Product Manufacturer Inspections During and After COVID-19

Restarting Clinical Trials in the Wake of COVID-19

Animal Drug Compounding: FDA’s New Guidance and Impacts on Industry

COVID-19 and Beyond: Development and Implementation of Recovery Action Plans for Medical Product Manufacturers

The Long-Awaited Biologics Transition Date Has Come: What Now?

Regulation of Over-the-Counter (OTC) Drugs: An Introduction

Medical Device Clinical Investigations: An Introduction to Investigational Device Exemptions (IDEs), Institutional Review Boards (IRBs) and Informed Consent

An Introduction to Coverage, Coding, and Payment of Medical Devices – Collaboration Between FDA and the Centers for Medicare and Medicaid Services (CMS)

An Introduction to the Regulation of Promotion and Advertising for Medical Devices

FDA Authorities and Processes for the Enforcement, Compliance, and Inspection of Medical Devices

Post Marketing Issues for Medical Devices: An Introduction

Medical Device Clinical Investigations: An Introduction to Sponsor Responsibilities and Compliance Issues

Overview of Medical Device Law and Regulation

International Issues for Medical Device Manufacturers: An Introduction

Regulatory Requirements for Medical Device Manufacturing and Quality System Regulation: An Introduction

Medical Device Manufacturer Requirements: An Introduction to Registration and Listing of Establishments

An Introduction to the Medical Device Approval Process: Premarket Notification 510(k) and De Novo Requests

Biologics License Applications (BLA): An Introduction

An Introduction to Violations, Enforcement, and International Issues in Biologics and Biosimilars

The Regulation of Biological Product Manufacturing: An Introduction

Post-Approval Pharmacovigilance of Biological Products: An Introduction

An Introduction to Biosimilar Product Regulation and Approval

Regenerative Medicine and Advanced Therapies: An Introduction

Regulation of Biological/Drug Development: An Introduction

Overview of Biological Products Law and FDA’s Regulatory Processes

An Introduction to Drug Enforcement: FDA Enforcement Authorities, Tools, Violations and Initiatives

Regulation of Drug Marketing: An Introduction

Regulation of Drug Manufacturing: An Introduction

Post Approval Requirements for Drugs: An Introduction to Safety Reporting and Post-Approval Changes

The Regulation of Biologics and Biosimilars: An Introduction

The New Drug Approval Process: An Introduction to the Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues

Origins and Overview of Drug Law Regulation: An Introduction

The New Drug Approval Process: Introduction to New Drug Research and Development

Introduction to FDA Review and Approval of Biological Products

New, Emerging, and Continually Interesting Issues

The New Drug Approval Process: NDA Submission and Review

The New Drug Approval Process: Basic Concepts

The Regulation of Biological Product Marketing: An Introduction

Medical Device Premarket Approval Applications (PMA) and the Humanitarian Device Exemption (HDE): An Introduction

FDA’s Recent COVID-19 Guidances Facilitating Expanded Access to Certain Medical Products

What are FDA’s Tools for Responding to Public Health Emergencies Such as the Coronavirus (COVID-19)?

The CREATES Act Has Passed: What Does It Mean for the Generics Industry?

Reducing Anti-Kickback Risks Associated with Medical Products

Introduction to Product Liability Regarding FDA-Regulated Products

Due Diligence: Ensuring Your Deal Doesn’t Collapse Due to Regulatory, Clinical, Quality, or Data Integrity Issues

Single, Shared System Risk Evaluation and Mitigation Strategies: Opportunities and Challenges

New Management Standards for Hazardous Waste Pharmaceuticals and Nicotine

Patient Assistance Programs: Recent Enforcement and Best Practices

Opioid Legislation: The Path Forward for FDA and DEA Webinar

From Approval to Coverage – FDA and CMS Jurisdictional Lines

Drug Pricing for the Food and Drug Community

Organic Chemistry for the Food and Drug Community

DEA Law for the Food and Drug Community

Data Integrity: FDA Enforcement and Risk-Reduction Considerations

New Medical Device Requirements and Where Manufacturers Should Focus: MDUFA, FDARA, and 21st Century Cures

Real World Evidence: Data Requirements, Utilization, and Presentation

Development of Medical Devices: Best Practices for Safeguarding Your IP and FDA Rights

PDUFA and BsUFA Reauthorization: Key Changes Affecting Industry and Patients

Key Regulatory Issues in Biosimilars

The EU’s New Medical Device and IVD Regulations

REMS: Key Issues and Best Practices

Compounding Still in the Mix: Title I of the DQSA, the Compounding Quality Act, Three Years Later

Recent FDA Guidance Documents on Manufacturer Communications about Medical Products

21st Century Cures Act

Open Payments Data and the Sunshine Act: Managing the Risk of Transparency

Medical Foods Regulation

admin2020-05-19T15:46:52-04:00